Retinopathy associated with high-dose interferon alfa-2b therapy.
OBJECTIVE
To present seven patients who developed retinopathy while receiving high-dose interferon alfa-2b therapy for adjuvant treatment of high-risk melanoma.


METHODS
Retrospective case series.


RESULTS
Seven patients developed a retinopathy while receiving high-dose interferon alfa-2b therapy for adjuvant treatment of high-risk melanoma. Five patients had normal visual acuity, but retinopathy with cotton- wool spots and/or retinal hemorrhages with the retinopathy resolved after stopping treatment after detection. Two patients developed severe retinopathy with vision loss to counting fingers and hand motions without resolution of the retinopathy. The duration of the maintenance treatment before detection of the retinopathy for all patients ranged from 6 to 26 weeks. The total dose received at time of detection of retinopathy ranged from 816 to 1770 million units. Confounding factors included hypertension, thrombocytopenia, anemia, and a history of prior chemotherapy in one patient. Also, one patient received an investigational ganglioside vaccine, one had a history of radiation treatment to the brain, and six received paroxetine.


CONCLUSIONS
Patients receiving interferon alfa-2b are at risk for developing an associated retinopathy. The risk appears to be greater with higher dosage therapy. In addition, severe vision loss can be seen with interferon alfa-2b-associated retinopathy. The effect of treatment with selective serotonin reuptake inhibitors, such as paroxetine, in increasing the incidence of this complication is unknown. Patients need to be monitored until the retinopathy is resolved to screen for sequelae, including retinal neovascularization.
Hejny
C
C
Department of Ophthalmology, Emory Eye Center and Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Sternberg
P
P
Lawson
D H
DH
Greiner
K
K
Aaberg
T M
TM
D004305:Dose-Response Relationship, Drug; D005260:Female; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects*; D008875:Middle Aged; D017374:Paroxetine / Q000627:therapeutic use; D011994:Recombinant Proteins; D012164:Retinal Diseases / Q000139:chemically induced* / Q000150:complications / Q000473:pathology; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D012720:Severity of Illness Index; D014786:Vision Disorders / Q000209:etiology / Q000503:physiopathology
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D017374:Paroxetine; D011994:Recombinant Proteins; D017367:Selective Serotonin Reuptake Inhibitors